BioVersys AG (SIX: BIOV) announced that the first patient has been dosed in a Phase 2b clinical trial evaluating alpibectir-ethionamide ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE